Novartis's COPD combo gets CHMP nod
This article was originally published in Scrip
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions for Novartis's chronic lung disease product Ultibro/Xoterna Breezhaler. It combines the long-acting muscarinic antagonist glycopyrronium bromide with the fast-acting beta-2 agonist indacaterol.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.